93 related articles for article (PubMed ID: 8090331)
1. Serum type I procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis?
Hamdy NA; Risteli J; Risteli L; Harris S; Beneton MN; Brown CB; Kanis JA
Nephrol Dial Transplant; 1994; 9(5):511-6. PubMed ID: 8090331
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy.
Mazzaferro S; Pasquali M; Ballanti P; Bonucci E; Costantini S; Chicca S; De Meo S; Perruzza I; Sardella D; Taggi F
Nephrol Dial Transplant; 1995; 10(1):52-8. PubMed ID: 7724029
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of biochemical markers in patients with metabolic bone disorders.
Hoshino H; Kushida K; Takahashi M; Kawana K; Denda M; Yamazaki K; Inoue T
Endocr Res; 1998 Feb; 24(1):55-64. PubMed ID: 9553754
[TBL] [Abstract][Full Text] [Related]
4. Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone.
Joffe P; Heaf JG; Jensen LT
Nephrol Dial Transplant; 1995 Oct; 10(10):1912-7. PubMed ID: 8592603
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
[TBL] [Abstract][Full Text] [Related]
6. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure.
Franke S; Lehmann G; Abendroth K; Hein G; Stein G
Eur J Med Res; 1998 Feb; 3(1-2):81-8. PubMed ID: 9512973
[TBL] [Abstract][Full Text] [Related]
7. Carboxyterminal propeptide of type I procollagen in osteomalacia.
Li F; Iqbal J; Wassif W; Kaddam I; Moniz C
Calcif Tissue Int; 1994 Aug; 55(2):90-3. PubMed ID: 7953986
[TBL] [Abstract][Full Text] [Related]
8. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients.
Coen G; Ballanti P; Bonucci E; Calabria S; Centorrino M; Fassino V; Manni M; Mantella D; Mazzaferro S; Napoletano I; Sardella D; Taggi F
Nephrol Dial Transplant; 1998 Sep; 13(9):2294-302. PubMed ID: 9761512
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases.
Santi I; Monti M; Viganò A; D'Aprile E; Rampoldi E; Castellani L; Accinni R; Cunietti E
Int J Biol Markers; 1995; 10(2):107-12. PubMed ID: 7561234
[TBL] [Abstract][Full Text] [Related]
10. Comparison between serum levels of bone alkaline phosphatase and the carboxy-terminal propeptide of type I procollagen as markers of bone formation in patients following renal transplantation.
Withold W; Degenhardt S; Grabensee B; Reinauer H
Clin Chim Acta; 1995 Aug; 239(2):143-51. PubMed ID: 8542652
[TBL] [Abstract][Full Text] [Related]
11. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
12. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
[TBL] [Abstract][Full Text] [Related]
13. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis.
Gerakis A; Hutchison AJ; Apostolou T; Freemont AJ; Billis A
Nephrol Dial Transplant; 1996 Dec; 11(12):2430-8. PubMed ID: 9017618
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
[TBL] [Abstract][Full Text] [Related]
15. Procollagen I carboxyterminal propeptide (PICP) as a bone formation marker and carboxyterminal telopeptide of type I collagen (ICTP) as a bone degradation marker in children with chronic renal failure under conservative therapy.
Polak-Jonkisz D; Zwolińska D; Bednorz R; Owczarek H; Szymańska A; Nahaczewska W
Med Sci Monit; 2003 Jan; 9(1):CR19-23. PubMed ID: 12552245
[TBL] [Abstract][Full Text] [Related]
16. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
[TBL] [Abstract][Full Text] [Related]
17. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
19. The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones.
Hassager C; Jensen LT; Johansen JS; Riis BJ; Melkko J; Pødenphant J; Risteli L; Christiansen C; Risteli J
Metabolism; 1991 Feb; 40(2):205-8. PubMed ID: 1988778
[TBL] [Abstract][Full Text] [Related]
20. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
Jarava C; Armas JR; Palma A
Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
